T1	Participants 55 96	patients with osteoarthritis of the knee.
T2	Participants 175 362	1578 patients with osteoarthritis randomized to take acetaminophen 4000 mg (n=269), celecoxib 200 mg (n=523), rofecoxib 12.5 mg (n=259), or rofecoxib 25 mg (n=527) in a double blind trial
